- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06220669
En studie av LY3541860 hos voksne deltakere med residiverende multippel sklerose
En adaptiv fase 2a/2b, randomisert, dobbeltblind, parallellgruppestudie for å undersøke sikkerheten og effekten av LY3541860 sammenlignet med placebo for å bremse forekomsten av nye T1 gadoliniumforsterkende lesjoner hos voksne deltakere med residiverende multippel sklerose
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Gulf Breeze, Florida, Forente stater, 32561
- Panhandle Research and Medical Clinic
-
Winter Park, Florida, Forente stater, 32789
- Conquest Research LLC - Winter Park - ClinEdge - PPDS
-
-
Illinois
-
Northbrook, Illinois, Forente stater, 60062
- Consultants in Neurology
-
-
Missouri
-
Ozark, Missouri, Forente stater, 65721-5315
- Sharlin Health and Neurology
-
-
South Carolina
-
Greer, South Carolina, Forente stater, 29605
- Premier Neurology
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37922
- Hope Neurology
-
-
-
-
-
Poissy, Frankrike, 78303
- Centre Hospitalier Intercommunal - Site de Poissy
-
-
-
-
-
Milan, Italia, 20133
- Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
-
-
-
-
-
Riga, Latvia, LV-1002
- Pauls Stradins Clinical Univeristy Hospital
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Neurocentrum Bydgoszcz sp. z o.o.
-
Katowice, Polen, 40-686
- NEURO-MEDIC Sp. z o. o.
-
Katowice, Polen, 40-060
- Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala
-
Katowice, Polen, 40-571
- M.A. - LEK A.M. Maciejowscy SC. Centrum Terapii SM
-
Lublin, Polen, 20-064
- Clinirem
-
Poznan, Polen, 61-853
- Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
-
Warsaw, Polen, 02-677
- ETG Neuroscience - PPDS
-
Zabrze, Polen, 41-800
- IBISMED Wielospecjalistyczne Centrum Medyczne
-
Żory, Polen, 44-240
- ProNeuro Centrum Medyczne
-
-
-
-
-
Bratislava, Slovakia, 826 06
- Nemocnica Ruzinov
-
-
-
-
-
Nottingham, Storbritannia, NG7 2UH
- Queen's Medical Centre
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.
-
Participants must have 1 of these:
- at least 1 documented relapse within the previous year
- at least 2 documented relapses within the previous 2 years, or
- at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.
-
Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (≤) 5.5 at screening and randomization.
Exclusion Criteria:
-
Have had a diagnosis of:
- primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or
- nonactive secondary progressive MS ( Klineova and Lublin 2018).
-
Meet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).
-
Have a history of clinically significant central nervous system (CNS) disease.
-
Have had a confirmed relapse with systemic corticosteroid administration <30 days prior to randomization.
-
Have more than 20 active GdE brain lesions on screening MRI scan.
-
Have received any of these medications or treatments.
-
Have a current or recent acute, active infection.
-
Have current serious or unstable illnesses.
-
Have any other clinically important abnormality at screening or baseline.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LY3541860 High Dose
Participants received a high dose of LY3541860 administered intravenously (IV) over a period of 36 weeks. |
Administered IV |
|
Eksperimentell: Placebo / LY3541860 Low Dose
Participants received LY3541860-matching placebo for 12 weeks, followed by a low dose of LY3541860 administered intravenously (IV) over a period of 24 weeks. |
Administered IV Administered IV |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions
Tidsramme: 12 Weeks
|
The cumulative number of new T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1). |
12 Weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cumulative Number of Total Number of T1 GdE Lesions
Tidsramme: 12 Weeks
|
The cumulative number of total number of T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1). |
12 Weeks
|
|
Cumulative Number of New and/or Enlarging T2 Lesions
Tidsramme: 12 Weeks
|
The cumulative number of new and/or enlarging T2 lesions identified on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) approach with a negative binomial regression outcome model adjusted for geographic region (North America vs Rest of World) and presence of T1 gadolinium-enhancing lesions at baseline (0 vs ≥1). |
12 Weeks
|
|
Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12
Tidsramme: Predose at Week 12
|
Observed Plasma trough concentrations (Ctrough) of LY3541860. |
Predose at Week 12
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 18548
- J3K-MC-KIAB (Annen identifikator: Eli Lilly and Company)
- 2023-503289-22-00 (Annen identifikator: EU Trial Number)
- 2023 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-delingstidsramme
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Tilgangskriterier for IPD-deling
research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .